What is Laboratorios Farmaceuticos Rovi PEG Ratio?
Laboratorios Farmaceuticos RoviFRA:41L +0.87%93 PEG Ratio is 1.54 as of Jul. 05, 2026, which is 60% above its 10-year median of 0.96. GuruFocus rates FRA:41L with a GF Score™ of 93/100 and a GF Value™ of €51.89 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 348 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 53.74% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's PEG Ratio or its related term are showing as below:
FRA:41L'
s PEG Ratio Range Over the Past 10 Years
Min: 0.14 Med: 0.96 Max: 313.42
Current: 1.51
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest PEG Ratio was 313.42. The lowest was 0.14. And the median was 0.96.
FRA:41L's PEG Ratio is ranked better than 53.74% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.7
vs FRA:41L: 1.51
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Laboratorios Farmaceuticos Rovi (FRA:41L) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Laboratorios Farmaceuticos Rovi PEG Ratio Related Terms
Laboratorios Farmaceuticos Rovi PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Laboratorios Farmaceuticos Rovi (FRA:41L) has a PEG Ratio of 1.54 as of Jul. 05, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 60% above median its historical median of 0.96. Over the past decade, Laboratorios Farmaceuticos Rovi's PEG Ratio has ranged from 0.14 to 313.42. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #161 out of 348 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Laboratorios Farmaceuticos Rovi's PEG Ratio too high?
Laboratorios Farmaceuticos Rovi's current PEG Ratio of 1.54 is 60% above median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 313.42. The Drug Manufacturers industry median PEG Ratio is 1.70. Laboratorios Farmaceuticos Rovi's value of 1.54 is 9.4% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #161 out of 348 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #161 out of 348 companies for PEG Ratio. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median PEG Ratio is 1.70. Laboratorios Farmaceuticos Rovi's value of 1.54 is 9.4% below this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own PEG Ratio has ranged from 0.14 to 313.42 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 1.70, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current PEG Ratio of 1.54 is 9.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current PEG Ratio is 1.54, which is 60% above median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Modestly Overvalued. The stock's GF Value™ is €51.89, compared to a current price of €57.90 — trading 11.6% above its estimated fair value. The current PEG Ratio is 1.54, which is 60% above median its 10-year median of 0.96 and 9.4% below the Drug Manufacturers industry median of 1.70. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current PEG Ratio is 1.54 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €57.90 is trading 11.6% above its estimated GF Value™ of €51.89.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for FRA:41L:
PEG Ratio: 1.54 (60% above median its 10-year median of 0.96)
GF Value™: €51.89 vs. price of €57.90 (11.6% above fair value)
Industry Position: 9.4% below the Drug Manufacturers median (#161 of 348)
No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for FRA:41L
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:41L has been successfully added to your 
